Benzinga | Mar 4, 2021 04:04PM EST

Acorda Therapeutics Q4 EPS $(2.50) Misses $(1.48) Estimate, Sales $38.16M Beat $34.00M Estimate

Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(2.50) per share which missed the analyst consensus estimate of $(1.48) by 68.92 percent. This is a 1566.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $38.16 million which beat the analyst consensus estimate of $34.00 million by 12.24 percent. This is a 24.43 percent decrease over sales of $50.50 million the same period last year.